Assessment of the incorporation of CNV surveillance into gene panel next-generation sequencing testing for inherited retinal diseases. by Ellingford, Jamie M et al.
1Ellingford JM, et al. J Med Genet 2017;0:1–8. doi:10.1136/jmedgenet-2017-104791
ORIGINAL ARTICLE
Assessment of the incorporation of CNV surveillance 
into gene panel next-generation sequencing testing 
for inherited retinal diseases
Jamie M Ellingford,1,2 Bradley Horn,1 Christopher Campbell,1 Gavin Arno,3 
Stephanie Barton,1 Catriona Tate,4 Sanjeev Bhaskar,1 Panagiotis I Sergouniotis,1 
Rachel L Taylor,1,2 Keren J Carss,5,6 Lucy F L Raymond,6,7 Michel Michaelides,3,8 
Simon C Ramsden,1 Andrew R Webster,3,8 Graeme C M Black1,2
Copy-number variation
To cite: Ellingford JM, 
Horn B, Campbell C, et al. 
J Med Genet Epub ahead of 
print: [please include Day 
Month Year]. doi:10.1136/
jmedgenet-2017-104791
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
jmedgenet- 2017- 104791).
For numbered affiliations see 
end of article.
Correspondence to
Graeme C M Black, Manchester 
Centre for Genomic Medicine, 
Manchester University NHS 
Foundation Trust, St Mary’s 
Hospital, Manchester M13 9WL, 
UK;  graeme. black@ manchester. 
ac. uk
Received 10 May 2017
Revised 20 September 2017
Accepted 9 October 2017
ABSTRACT
Background Diagnostic use of gene panel next-
generation sequencing (NGS) techniques is commonplace 
for individuals with inherited retinal dystrophies (IRDs), 
a highly genetically heterogeneous group of disorders. 
However, these techniques have often failed to capture 
the complete spectrum of genomic variation causing IRD, 
including CNVs. This study assessed the applicability of 
introducing CNV surveillance into first-tier diagnostic 
gene panel NGS services for IRD.
Methods Three read-depth algorithms were applied to 
gene panel NGS data sets for 550 referred individuals, 
and informatics strategies used for quality assurance and 
CNV filtering. CNV events were confirmed and reported 
to referring clinicians through an accredited diagnostic 
laboratory.
Results We confirmed the presence of 33 deletions and 
11 duplications, determining these findings to contribute 
to the confirmed or provisional molecular diagnosis of 
IRD for 25 individuals. We show that at least 7% of 
individuals referred for diagnostic testing for IRD have a 
CNV within genes relevant to their clinical diagnosis, and 
determined a positive predictive value of 79% for the 
employed CNV filtering techniques.
Conclusion Incorporation of CNV analysis increases 
diagnostic yield of gene panel NGS diagnostic tests for 
IRD, increases clarity in diagnostic reporting and expands 
the spectrum of known disease-causing mutations.
INTRODUCTION
Inherited retinal dystrophies (IRDs) are a set of 
genetic disorders that have a diverse pathogenesis 
and are characterised by extreme genetic and clin-
ical heterogeneity.1 2 They are the leading cause of 
blindness in working-age adults in the UK,3 and are 
present in a range of multisystemic disorders, such 
as Usher syndrome and Senior-Loken syndrome. 
Identifying the genetic basis of IRDs can greatly 
assist the clinical diagnosis, counselling, treatment 
and management received by referred individuals.4 
As a result, a number of genomic diagnostic tests are 
available for individuals with IRD, including SNP 
microarrays, direct sequencing approaches, array 
comparative genomic hybridisation (array CGH) 
and high-throughput sequencing (commonly 
referred to as next-generation sequencing, NGS).5 
Despite the emergence of whole exome6 and 
whole genome NGS approaches,7 gene panel NGS 
approaches remain a major first-tier diagnostic 
test. This is due to their affordability, specificity, 
high coverage and proven capability to characterise 
disease-causing single nucleotide variations (SNVs) 
and small insertion and deletion events (indels).8 9 
However, the informatics techniques used to detect 
genetic variation from gene panel NGS diagnostic 
services have often failed to truly characterise the 
spectrum of disease-causing variation within the 
IRDs, including the relative contribution of large 
structural variation and CNV.
CNVs result in the gain or loss of genomic 
material and are known to cause IRD.10 However, 
the insertion and breakpoints of CNVs are often 
deeply intronic or intergenic, and as a result are not 
captured by gene panel NGS approaches employed 
in diagnostic environments, which focus primarily 
on protein-coding regions and proven patho-
genic intronic variants. This creates limitations in 
the types of variant detection algorithms that can 
be applied to gene panel NGS data sets to detect 
CNVs.11 Read-depth approaches for the surveil-
lance of CNVs, with complementary quality assur-
ance parameters, have recently been applied to gene 
panel NGS data sets in a diagnostic context.12–14 
Moreover, recent studies investigating the role of 
CNVs in IRDs have identified an enrichment of 
disease-causing CNVs among individuals without 
a genetic diagnosis through gene panel NGS 
techniques,7 15 and demonstrated the capability 
of high-resolution array CGH,16 whole exome 
sequencing (WES)17 and whole genome sequencing 
(WGS)7 18 to identify CNVs within and encom-
passing these surveyed genes. While the potential 
to identify CNVs from gene panel NGS data sets 
for IRD has been shown,19 this analysis is yet to 
be extended to a large cohort of individuals using 
comprehensive NGS gene panels generated through 
accredited diagnostic services. As such, knowledge 
of the relative benefits and limitations of intro-
ducing CNV surveillance into first-tier diagnostic 
gene panel NGS services for IRD remains limited.
In this study, we have expanded the assessment of 
gene panel NGS diagnostic data sets to include CNV 
analysis among a large cohort of 550 individuals 
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with IRD. Through comparison to WGS samples, we demon-
strate the advantages and limitations of this approach, and illus-
trate an informatics workflow for the analysis of CNVs identified 
from gene panel NGS data sets. Taken together, incorporation of 
CNV analysis increases the diagnostic yield of a major first-tier 
diagnostic test for IRD, increases clarity in diagnostic reporting 
and expands the spectrum of known disease-causing mutations.
MATERIALS AND METHODS
Recruitment of patients for CNV analysis
We performed CNV analyses for 550 individuals with clinical 
indications of IRD. All individuals provided consent for the 
comprehensive analysis of variation in genes known as a cause of 
IRD and were referred for diagnostic genetic testing by clinicians 
at Manchester Royal Eye Hospital and Moorfields Eye Hospital, 
London.
Generation of gene panel NGS data sets
DNA was extracted from the peripheral blood of referred indi-
viduals and enriched for specified regions of the genome using an 
Agilent SureSelect Custom Design target-enrichment kit (Agilent, 
Santa Clara, California, USA). Enrichment kits were designed 
to capture known pathogenic intronic variants and the protein-
coding regions ±50 nucleotides of selected National Center for 
Biotechnology Information (NCBI) RefSeq transcripts for 105 or 
180 genes known as a cause of IRD (online supplementary table 
S1). Full details of the genes and analysis techniques used during 
the 105-gene diagnostic testing procedure (referred to as v2) can 
be found in Ellingford et al9 and through the UK Genetic Testing 
Network (https:// ukgtn. nhs. uk/ find- a- test/ search- by- disorder- 
gene/ retinal- degeneration- 105- gene- panel- 568/). The 180-gene 
panel (referred to as v3) represents an expanded iteration of 
this diagnostic service within the UK National Health Service, 
with the additional inclusion of enrichment baits to capture (1) 
selected pathogenic intronic variants; and (2) additional genes 
known as a cause of IRD, including newly identified genes and 
genes known as a cause of congenital stationary night blindness. 
After enrichment, samples were pooled using unique barcode 
identifiers, and paired-end high-throughput sequencing was 
performed using the Illumina HiSeq 2000/2500.
Detection of CNVs from gene panel NGS data sets using 
ExomeDepth
Sequencing reads were demultiplexed with CASAVA V.1.8.2 and 
aligned to the hg19 reference genome using Burrows-Wheeler 
Aligner short read (V.0.6.2) software.20 Duplicate reads were 
removed using SAMtools V.0.1.18 before variant calling was 
performed. We have described the methodology employed for 
the detection and clinical analysis of SNVs and indels previ-
ously.9 CNV detection was performed using standard parame-
ters for ExomeDepth V.1.1.6.21 ExomeDepth was presented with 
sets of aligned and non-duplicate sequencing reads in a binary 
sequence alignment/map (BAM) file format that were matched 
by gender and by the enrichment kit used, and had been gener-
ated for unrelated individuals with IRD referred for diagnostic 
testing (online supplementary table S2).
Informatics filtering strategies
We used three distinct strategies to limit the number of potential 
false-positive CNV events identified by ExomeDepth (figure 1). 
Events that were analysed in a clinical context were all (1) identi-
fied against three independent reference sets using ExomeDepth, 
(2) identified by at least one other CNV software tool (CoNVex,22 
CoNVaDING12 or both) and (3) visually inspected using the 
ExomeDepth graphical package.
We first limited our analysis of CNV events to those that had 
been identified by ExomeDepth in comparison to three mutually 
exclusive reference sets of samples. For each tested individual we 
created three randomly selected and non-overlapping groups of 
30 individuals matched by their gender and the enrichment kit 
used and presented these to the ExomeDepth algorithm. The 
overlap between the three reference sets was calculated using 
bedtools V.2.25.0 intersect. Second, we performed CNV calling 
using two other publicly available CNV detection algorithms 
(CoNVex and CoNVaDING). Both algorithms were presented 
with aligned and non-duplicate sequencing reads in a BAM file 
format for large groups of individuals matched by gender and the 
enrichment kit used (as described in online supplementary table 
S2), and CNV calling was performed using standard parameters 
for each of these tools. We compared CNV events identified by 
CoNVex and CoNVaDING with those that had been identified 
by ExomeDepth using bedtools V.2.25.0 intersect, and included 
all events identified by ExomeDepth and at least one other CNV 
detection tool. We limited our third stage of analysis, visual 
inspection, to those events that were identified against three 
reference sets using ExomeDepth and by at least one additional 
CNV detection tool. Visual inspection included an assessment of 
the consistency of calculated read ratios across all exons within 
implicated genes, the extent of variation within the selected 
reference samples for each exon, the nature of the exon CNV 
status across the cohort and the continuity of abnormal CNV 
exons within the implicated gene.
Clinical analysis of CNV events
CNVs were interpreted alongside SNVs and indels that had been 
detected through routine gene panel NGS diagnostic techniques, 
as described previously.9 For each individual, variants were cate-
gorised in accordance with the American College of Medical 
Genetics and Genomics (ACMG) guidelines,23 and pathogenic/
likely pathogenic variants in a disease-causing state were deter-
mined to confirm or provisionally confirm a molecular diagnosis 
of IRD. CNV frequency estimations were calculated through 
comparison to 682 WGS data sets for individuals with clinical 
Figure 1 Informatics strategies used to filter CNVs identified by 
ExomeDepth. Taken together, these strategies had a positive predictive 
value of 79%. SNV, single nucleotide variation; WGS, whole genome 
sequencing.
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indications of IRD. Six hundred and five samples were gener-
ated using Illumina sequencing chemistry as part of the National 
Institute for Health Research (NIHR) BioResource Rare Diseases 
project,18 and the Manta and Canvas software algorithms were 
used to detect CNVs.24 25 Seventy-seven samples were generated 
using Complete Genomics sequencing chemistry,26 with CNVs 
identified using the Complete Genomics V.2.5 variant calling 
pipeline.27 Both of these strategies incorporate an assessment of 
sequencing read depth, an assessment of the read insert sizes and 
an assessment of sequencing read composition to identify CNV 
breakpoints/insertion points.
Confirmation of identified CNVs
CNVs were confirmed as present before they were reported 
to referring clinicians. Where kits designed and created by 
MRC-Holland (Amsterdam, The Netherlands) were available, 
we carried out multiplex ligation-dependent probe amplification 
(MLPA) assays. In the absence of a suitable MLPA kit, we vali-
dated CNVs using a digital droplet PCR or a quantitative fluo-
rescence methodology, as described previously.14
Estimating accuracy for CNV identification
To ensure that the NGS data surveyed were appropriate for 
CNV surveillance, we calculated a series of sequencing coverage 
metrics. We have provided a full description of these calculated 
metrics and their utility previously,14 and these included (1) NGS 
coverage and normalised coverage for surveyed exons, (2) levels 
of insufficient coverage (<50 unique NGS reads) for surveyed 
nucleotides and exons, and (3) intersample variability, defined as 
the coefficient of variation of normalised NGS coverage across 
samples selected as the reference set by ExomeDepth.
RESULTS
CNV identification and filtering strategies
We performed CNV calling for 550 individuals with IRD using 
gene panel NGS data sets generated through diagnostic testing 
in a clinically accredited laboratory (197 v2 gene panel, 105 
genes; 353 v3 gene panel, 180 genes). CNV surveillance was 
performed using ExomeDepth V.1.1.6. for four groups of indi-
viduals matched by their gender and the enrichment kit used 
during gene panel NGS (online supplementary table S2). In total, 
we identified 117 potential deletion events and 70 potential 
duplications through ExomeDepth  (online supplementary table 
S3). This equated to an average of one CNV event per three 
individuals tested (min=0, max=16), although we observed 
a trend of no CNVs identified for most samples (n=429) and 
more than one CNV identified in few samples (n=23; online 
supplementary figure S1). We applied three distinct strategies for 
CNV filtering (see online supplementary methods and results) in 
order to identify true CNV events, and these analyses identified 
56 CNV events (30% of the original 187) for further confirma-
tion and clinical analysis (figure 1). To assess the accuracy of 
informatics filtering approaches, 13 events that were excluded 
through comparison to other CNV detection algorithms were 
also selected for further confirmation (online supplementary 
results).
Estimating accuracy for CNV identification
Through previous investigations we have identified that the 
level of NGS coverage in tested samples and the extent of vari-
ation in NGS coverage across selected reference samples (inter-
sample variability) are both key influencers of the accuracy of 
ExomeDepth applied to gene panel NGS data sets. In total, 
we surveyed 1 267 742 exons for CNVs (1590 exons in 197 
cases and 2704 exons in 353 cases), with an average of 2389 
unique NGS reads generated per exon (min=0, max=202 357, 
median=1579, SD=4013.7). We observed that >50 unique 
NGS reads were generated for all the nucleotides included 
within 99.2% (n=1 257 794) of the surveyed exons, although 
we were unable to accurately survey the CNV status for eight 
exons included within the v2 panel (105 genes) due to consis-
tently poor coverage across the cohort (online supplementary 
table S4). Consistently poor coverage was not observed across 
individuals surveyed through the newer v3 gene panel (180 
genes; online supplementary table S4).
The average normalised NGS coverage profiles for each 
exon were calculated, and extensive variability was observed 
across the complete cohort, with average intersample variability 
values per exon of 21.1% (n, exons=313 230) and 22.2% (n, 
exons=954 512) for the v2 and v3 gene panels, respectively 
(online supplementary figure S2). Intersample variation was 
reduced to 5.83% (n exons=1 224 686, median=5.25%, 
SD=3.28%), when observations were limited to the extent 
of variation among samples selected as the reference set by 
ExomeDepth for each tested sample. There were 43 056 exons 
excluded from this analysis due to the selection of a solitary 
sample as the reference set by ExomeDepth (n=41 512) or as a 
result of consistently poor coverage (n=1544). In comparison to 
previously published simulation data sets,14 95% and 99% of the 
surveyed exons are consistent with an accuracy for single exon 
deletions of 98.7% and 98.2%, respectively (online supplemen-
tary figure S3).
Confirmation of CNVs and clinical outcomes
We confirmed 44/56 CNV events through orthogonal tech-
niques, determining a positive predictive value (PPV) of 79% 
for the informatics filtering strategies employed in this study 
(figure 1, online supplementary results). Expanding confirma-
tions to also include 13 events excluded through comparison 
to other CNV detection algorithms confirmed the presence of 
a single likely benign duplication event in NPHP1 (14016366; 
NM_000272.3:c.(?_−1)_(*1_?)dup) but reduced the PPV to 
65.2% (45/69). In confirming these findings, we determined a 
molecular diagnosis or a provisional molecular diagnosis for 25 
individuals and additional findings that did not account for a 
molecular diagnosis for 18 individuals (table 1). These results 
were obtained after full appraisal of the clinical indication of 
IRD for the referred individual and the analysis of SNVs and 
small indels from routine gene panel NGS testing. Of note, a 
single individual was confirmed with two independent hetero-
zygous CNV events, neither of which was determined to 
account for a molecular diagnosis (13009597; table 1). Routine 
testing identified a pathogenic missense variant in SNRNP200 
(NM_014014.3: c.2042G>A, p.(Arg681His)), accounting for 
a diagnosis of autosomal dominant retinitis pigmentosa for 
this individual, with no pathogenic/likely pathogenic variants 
identified in-trans to the confirmed heterozygous deletion of 
IDH3B and MKKS. Of the 25 CNVs that enabled the confir-
mation or provisional confirmation of diagnosis, 23 confirmed 
autosomal recessive disorders and 2 confirmed autosomal 
dominant disorders (online supplemetary table S5). Twenty of 
these CNV events were confirmed in a heterozygous state, with 
18 of the events suspected (n=8) or confirmed (n=10) to be 
in-trans to a heterozygous and proven/potentially pathogenic 
SNV or indel confirmed within the same gene (online supple-
mentary table S5). Confirmation of in-trans variants included 
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the encapsulation of an apparently homozygous SNV/indel 
by a heterozygous deletion event and/or familial segregation 
analysis. For example, a heterozygous whole gene deletion of 
RPE65 (NM_000329.2) was identified for an individual origi-
nally described with a clearly pathogenic homozygous missense 
variant (NM_000329.2: c.1102T>C, p.(Tyr368His)). Subse-
quent familial segregation analysis confirmed these events to be 
paternally and maternally inherited, respectively. Five homozy-
gous CNV events were confirmed to account for a molecular 
diagnosis for referred individuals, including four homozygous 
deletions (table 1) and a single duplication event confirmed as 
four copies of EYS exons 34–35 (NM_001142800.1).
We confirmed that seven ‘likely pathogenic’ deletions were 
present in a carrier state, including two whole gene deletions, 
two deletions predicted to cause a frameshift and three inframe 
deletions. These events were all described in genes known as a 
cause of IRD or associated syndromic disorders that are inher-
ited in an autosomal recessive manner, including BBS2, BBS4, 
CDH3, CLN3, GRM6, NPHP1, and a deletion spanning IDH3B 
and MKKS (table 1).
Duplications proved more complex for clinical interpretation, 
and based on current evidence most of the identified duplica-
tions were classified as ‘uncertain significance’ (45%, n=5) or to 
be ‘likely benign’ (36%, n=4).
In four individuals, we identified heterozygous CNV events 
in genes known as a cause of autosomal dominant Mendelian 
disorders that were not determined to be a cause of disease 
for the referred individual (table 1). These included a three-
exon deletion in RP1L1 (NM_178857.5), a single-exon dele-
tion in FSCN2 (NM_001077182.2), a single-exon deletion in 
RGR (NM_002921.3) and a duplication event impacting RP9 
(NM_203288.1) and BBS9 (NM_198428.2). Of note, we also 
identified four copies of PRPF31 exons 2–8 (NM_015629.3) 
in an additional individual. Based on current evidence, the 
PRPF31 duplication was classified as ‘uncertain significance’ 
(online supplementary case study), although we expect future 
investigations to assist with the interpretation of this variant.
Population and in-house frequencies of identified CNV events
To assist with clinical interpretation, the frequency of confirmed 
CNV events was determined through comparison to two inde-
pendently acquired cohorts of WGS data sets generated for indi-
viduals with a clinical indication of IRD (605 through the NIHR 
BioResource Rare Diseases project using Illumina sequencing, 
and 77 through Complete Genomics sequencing). Of the 
44 confirmed CNV events reported in this study, 25 (57%) 
were found to have an overlap with events identified through 
WGS. This analysis was restricted to events identified through 
WGS, which overlapped at least 50% of the event identified 
through gene panel NGS. Three of these samples with identi-
fied CNV events were also included in the WGS cohorts (two 
from Illumina sequencing and one from Complete Genomics 
sequencing), enabling an assessment of the relative advantages 
for detecting CNVs through WGS in comparison to gene panel 
NGS (online supplementary figures S4 ,S5 and table 6) (should 
be table S6).Seven events were identified to have an overlap with 
more than one individual within the WGS cohorts (table 2). Of 
note, a confirmed duplication of RP9/BBS9 was identified in four 
unrelated WGS samples through Illumina sequencing (online 
supplementary figure S5). This information, in complement to 
other confirmed SNVs/indels for these individuals, permitted 
the classification of this duplication event as ‘uncertain signif-
icance’ and unlikely to account for the individual’s molecular S
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diagnosis. Similarly, whole gene duplication events of NPHP1 
and CYP4V2 were identified in multiple unrelated individuals 
across the cohorts, and the absence of a second disease-causing 
mutation in these genes in all reported cases suggests they may 
represent benign variation. Future investigations into the patho-
genicity of whole gene duplication events will assist with inter-
pretation and will provide greater clarity in clinical reporting. 
These investigations may consist of WGS and/or long-read NGS 
to better characterise the location and phase of duplications, and 
RNA-seq experiments to assess the effect of duplications on gene 
expression.
DISCUSSION
A variety of techniques exist for the identification of genomic 
CNVs, including MLPA, Q-PCR, genome-wide and custom-
ised array CGH, and low-coverage genome-wide sequencing.11 
The detection of CNVs from high-coverage NGS data provides 
the unique opportunity for the simultaneous analysis of novel 
disease-causing SNVs and small indels, a strategy that has proved 
extremely successful for the diagnosis of IRD.9 While a number 
of informatics techniques exist for the identification of CNVs 
from NGS data sets,28 gene panel NGS approaches are limited 
by the types of CNV detection algorithms which can be routinely 
applied. Here, we describe an implemented informatics strategy 
using read-depth algorithms for the identification of CNVs from 
gene panel NGS data sets for 550 individuals with IRD. Through 
these strategies, we have confirmed 33 deletions and 11 dupli-
cations (table 1), determining these findings to contribute to the 
molecular diagnosis or provisional molecular diagnosis of IRD 
for 25 individuals (online supplementary table S5).
This study provides the largest cohort, to date, for the assess-
ment of the relative frequency of CNVs as a cause of IRD from 
targeted NGS data sets. Our group and others have estimated 
the contribution of CNVs in IRDs from smaller cohorts of indi-
viduals, including high-resolution array CGH approaches (3.5%, 
n=57),16 gene panel NGS (3.1%, n=126; 1.1%, n=89; 6.4%, 
n=47),19 29 30 WES (10%, n=60)17 and WGS (10.9%, n=46; 
12.5%, n=16).7 31 Here, we show that CNVs contribute to a 
molecular diagnosis of IRD in 4.5% of cases, and are found 
without contribution to a molecular diagnosis in a further 3.3% 
of cases. Altogether, we estimate that a CNV is present within 
IRD genes in at least 1 in 13 individuals presenting with IRD, 
and thereby provides a significant and essential component of 
the diagnostic assessment.
The incorporation of read-depth CNV detection algorithms 
into gene panel NGS diagnostic services for IRD provides a 
realistic and cost-effective opportunity for widespread incorpo-
ration of CNV analysis. However, false-negative assessments, 
false-positive discoveries, complexity with clinical interpretation 
and the size of events that can be detected all provide signifi-
cant limitations to this approach.32 To overcome these challenges 
in this study, we compared the results from ExomeDepth with 
two other publicly available CNV detection algorithms with 
the capability to detect single-exon CNV events (CoNVex22 
and CoNVaDING12) and used distinct strategies for CNV 
filtering to reduce the number of false-positive events analysed 
(figure 1). These filtering approaches provided a PPV of 79% 
(44/56) and enabled the confirmation of events with a range 
of confidence scores calculated by the ExomeDepth algorithm 
(min=6.7, max=424), including 11 single-exon deletions and 
one single-exon duplication. Furthermore, we assessed two key 
quality assurance parameters previously identified as key deter-
minants of false-negative assessments through ExomeDepth: 
insufficient coverage and intersample variability.14 We identi-
fied that 99.2% of surveyed exons had appropriate sequencing 
coverage for CNV surveillance in tested samples and that 99% of 
exons were consistent with a 98.2% accuracy of ExomeDepth in 
comparison to 1000 previously reported simulated single-exon 
deletion events.14 Importantly, the frequency of CNVs reported 
for this cohort are concordant with a recent study that inter-
rogated rare variants in 224 IRD-associated genes from WGS 
data sets for 605 individuals with IRD,18 and these data provide 
additional support for the sensitivity of the methodologies 
applied to gene panel NGS data sets in this study.
We have described CNVs in 36 different genes. The genes most 
frequently identified with CNVs were EYS (n=5), USH2A (n=4) 
and NPHP1 (n=4) (table 1). These data are in accordance with 
recent findings that have identified factors underpinning suscep-
tibility of IRD genes to CNVs.33 Microhomology-mediated DNA 
repair mechanisms (eg, microhomology-mediated break-induced 
replication) have been proposed as a major contributor to the 
genesis of non-recurrent CNVs.33 34 Our data sets precluded a 
comprehensive assessment of CNV mechanisms. However, it is 
notable that we have observed small stretches of microhomology 
between proximal and distal genomic sequences at breakpoints 
for non-recurrent CNVs (online supplementary table S6). We 
have also identified several instances of a recurrent duplication 
and a recurrent deletion of the complete coding region of NPHP1 
(NM_000272.3), which are expected to have arisen through 
non-allelic homologous recombination between segmental 
duplications flanking NPHP1.35 The deletion of NPHP1 has 
been frequently reported as a cause of autosomal recessive juve-
nile nephronophthisis and Senior-Loken syndrome. The emer-
gence of long-read NGS techniques to study CNVs will likely 
assist in the comprehensive characterisation of structural variant 
breakpoints, the elucidation of CNV genesis mechanisms, and 
the existence of ancestral and susceptibility haplotypes for CNVs 
that impact IRD genes.
In total we confirmed 44 CNV events through the described 
informatics strategies (figure 1), including 12 whole gene events, 
6 events removing or duplicating the canonical start or end 
codon, and 26 intragenic events. These strategies validated the 
presence of 28% and 16% of the deletions and duplications orig-
inally identified by ExomeDepth, respectively (figure 1). While 
these data suggest that IRD genes are more susceptible to dele-
tion than duplication, our observations may be a limitation of 
the approaches applied, as NGS read-depth CNV detection soft-
ware has been shown to be less sensitive for small duplication 
Table 2 CNVs identified in more than one unrelated individual
CNV event
CNV type Individuals (n)
Total
Gene 
panel NGS, 
n=550
WGS 
(Illumina) 
n=605
WGS 
(Complete 
Genomics) 
n=77
CLN3 ex8-9 Del 6 1 5 0
MERTK ex1-7 Del 3 1 1 1
NPHP1 (whole 
gene)
Del/Dup 7/10 1/3 5/6 1/1
RP9/BBS9 Dup 5 1 4 0
CNGB3 ex9-10 Del 4 1 3* 0
CYP4V2 (whole 
gene)
Dup 5 1 4 0
*Indicated, but unconfirmed, as CNGB3 ex7-10 for two individuals, and CNGB3 
ex8-10 for one individual using the Canvas read-depth algorithm.
Del, deletions; dup, duplications; NGS, next-generation sequencing; WGS, whole 
genome sequencing.
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events.36 Duplications also proved more challenging for clinical 
interpretation as we were unable to determine phase of appar-
ently homozygous events or confirm the genomic location of 
duplicated sequences. Both of these identified challenges may 
be overcome by the application of split-read and discordant 
read-pair algorithms to WGS data sets.28 A duplication iden-
tified in PRPF31, confirmed to be two extra copies of exons 
2–8, proved particularly problematic for clinical interpretation 
(online supplementary case study). Recently, Ayuso et al identi-
fied that a heterozygous duplication in PRPF31, encompassing 
exons 2–5, significantly reduced gene expression of PRPF31 
and underpinned clinical presentation of retinitis pigmentosa.37 
These results are consistent with the haploinsufficient patho-
genic mechanism of mutations in PRPF31 and other pre-mRNA 
splicing factor genes.38 However, mutations in PRPF31 are 
often reported with incomplete penetrance,38 and the patient 
identified with this duplication in our cohort also carried a 
homozygous variant in another gene surveyed through gene 
panel NGS that could account for their molecular diagnosis of 
IRD  (online supplementary case study). Future assessments of 
the location of duplicated sequences and their effect on PRPF31 
gene expression will assist with clinical interpretation and will 
be of great interest.
Interestingly, we also identified a number of genes that were 
absent from CNVs, including ABCA4, one of the most prevalent 
causes of IRD and a gene commonly identified to be in a carrier 
state in tested individuals. While it is possible that sequencing 
data generated for ABCA4 have characteristics that reduce the 
accuracy of the read-depth CNV detection techniques described 
here, none of the three applied algorithms identified deletions or 
duplications disrupting or encapsulating ABCA4, the sequencing 
profile is consistent with accurate surveillance of CNVs (online-
supplementary table S7), and these findings are consistent with 
the absence and rare occurrence of CNVs in ABCA4 in studies 
using WGS and array CGH for CNV interrogation.18 39 40
Taken together, we demonstrate that CNVs provide a signifi-
cant contribution towards the onset of IRD. We show that read-
depth algorithms applied to gene panel NGS data sets generated 
for individuals with IRD can identify deletion and duplication 
events ranging from single exons to multigene events, and 
provide compelling evidence for the routine incorporation of 
CNV analysis as a first-tier diagnostic test for individuals with 
IRD.
Author affiliations
1Manchester Centre for Genomic Medicine, Manchester Academic Health Sciences 
Centre, Manchester University NHS Foundation Trust, St Mary’s Hospital, Manchester, 
UK
2Division of Evolution and Genomic Sciences, Neuroscience and Mental Health 
Domain, School of Biological Sciences, Faculty of Biology, Medicine and Health, 
University of Manchester, Manchester, UK
3Department of Genetics, UCL Institute of Ophthalmology, London, UK
4Congenica, Wellcome Genome Campus, Hinxton, Cambridge, UK
5Department of Haematology, University of Cambridge NHS Blood and Transplant 
Centre, Cambridge, UK
6Department of NIHR BioResource – Rare Diseases, Cambridge University Hospitals 
NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
7Department of Medical Genetics, Cambridge Institute for Medical Research, 
University of Cambridge, Cambridge, UK
8Moorfields Eye Hospital NHS Foundation Trust, London, UK
Correction notice This article has been corrected since it was published Online 
First. A typo has been corrected.
Acknowledgements We thank all patients, referring clinicians, clinical scientists 
and genetic counsellors involved in this study. This work made use of data from the 
NIHR BioResource – Rare Diseases project.
Contributors JME and GCMB designed and coordinated the study. All authors 
contributed genetic and/or phenotypic data. JME wrote the manuscript, and all 
authors provided important revisions and intellectual content.
Funding This work was supported by the Biotechnology and Biological Sciences 
Research Council Biotechnology and Biological Sciences Research Council [grant 
code BB/J014478/1], the Manchester Biomedical Research Centre, the National 
Institute for Health Research Biomedical Centre at Moorfields Eye Hospital and 
the UCL Institute of Ophthalmology, RP Fighting Blindness and Fight for Sight 
(RP Genome Project GR586), the Cambridge Biomedical Research Centre, and an 
independent research grant funded by the Manchester Academic Health Science 
Centre. 
Competing interests CT is an employee of Congenica Ltd. All other authors 
declare no competing interests.
Patient consent Detail has been removed from this case description/these case 
descriptions to ensure anonymity. The editors and reviewers have seen the detailed 
information available and are satisfied that the information backs up the case the 
authors are making.
Ethics approval Greater Manchester West Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the 
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits 
others to distribute, remix, adapt and build upon this work, for commercial use, 
provided the original work is properly cited. See: http:// creativecommons. org/ 
licenses/ by/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
REFERENCES
 1 Wright AF, Chakarova CF, Abd El-Aziz MM, Bhattacharya SS. Photoreceptor 
degeneration: genetic and mechanistic dissection of a complex trait. Nat Rev Genet 
2010;11:273–84.
 2 Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal 
and vitreoretinal diseases. Prog Retin Eye Res 2010;29:335–75.
 3 Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness 
certifications in England and Wales in working age adults (16-64 years), 1999-2000 
with 2009-2010. BMJ Open 2014;4:e004015.
 4 Ellingford JM, Sergouniotis PI, Lennon R, Bhaskar S, Williams SG, Hillman KA, 
O’Sullivan J, Hall G, Ramsden SC, Lloyd IC, Woolf AS, Black GC. Pinpointing clinical 
diagnosis through whole exome sequencing to direct patient care: a case of Senior-
Loken syndrome. Lancet 2015;385:1916.
 5 Lee K, Garg S. Navigating the current landscape of clinical genetic testing for inherited 
retinal dystrophies. Genet Med 2015;17:245–52.
 6 Lee H, Deignan JL, Dorrani N, Strom SP, Kantarci S, Quintero-Rivera F, Das K, Toy 
T, Harry B, Yourshaw M, Fox M, Fogel BL, Martinez-Agosto JA, Wong DA, Chang 
VY, Shieh PB, Palmer CG, Dipple KM, Grody WW, Vilain E, Nelson SF. Clinical 
exome sequencing for genetic identification of rare Mendelian disorders. JAMA 
2014;312:1880.
 7 Ellingford JM, Barton S, Bhaskar S, Williams SG, Sergouniotis PI, O’Sullivan J, Lamb JA, 
Perveen R, Hall G, Newman WG, Bishop PN, Roberts SA, Leach R, Tearle R, Bayliss S, 
Ramsden SC, Nemeth AH, Black GC. Whole genome sequencing increases molecular 
diagnostic yield compared with current diagnostic testing for inherited retinal disease. 
Ophthalmology 2016;123:1143–50.
 8 Consugar MB, Navarro-Gomez D, Place EM, Bujakowska KM, Sousa ME, Fonseca-Kelly 
ZD, Taub DG, Janessian M, Wang DY, Au ED, Sims KB, Sweetser DA, Fulton AB, Liu Q, 
Wiggs JL, Gai X, Pierce EA. Panel-based genetic diagnostic testing for inherited eye 
diseases is highly accurate and reproducible, and more sensitive for variant detection, 
than exome sequencing. Genet Med 2015;17.
 9 Ellingford JM, Barton S, Bhaskar S, O’Sullivan J, Williams SG, Lamb JA, Panda B, 
Sergouniotis PI, Gillespie RL, Daiger SP, Hall G, Gale T, Lloyd IC, Bishop PN, Ramsden 
SC, Black GC. Molecular findings from 537 individuals with inherited retinal disease. J 
Med Genet 2016:761–7.
 10 Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN. The human gene 
mutation database: building a comprehensive mutation repository for clinical and 
molecular genetics, diagnostic testing and personalized genomic medicine. Hum 
Genet 2014;133:1–9.
 11 Alkan C, Coe BP, Eichler EE. Genome structural variation discovery and genotyping. 
Nat Rev Genet 2011;12:363–76.
 12 Johansson LF, van Dijk F, de Boer EN, van Dijk-Bos KK, Jongbloed JD, van der Hout AH, 
Westers H, Sinke RJ, Swertz MA, Sijmons RH, Sikkema-Raddatz B. CoNVaDING: Single 
Exon Variation Detection in Targeted NGS Data. Hum Mutat 2016;37:457–64.
 13 Pugh TJ, Amr SS, Bowser MJ, Gowrisankar S, Hynes E, Mahanta LM, Rehm HL, Funke 
B, Lebo MS. VisCap: inference and visualization of germ-line copy-number variants 
from targeted clinical sequencing data. Genet Med 2016;18:712–9.
group.bmj.com on January 22, 2018 - Published by http://jmg.bmj.com/Downloaded from 
8 Ellingford JM, et al. J Med Genet 2017;0:1–8. doi:10.1136/jmedgenet-2017-104791
Copy-number variation
 14 Ellingford JM, Campbell C, Barton S, Bhaskar S, Gupta S, Taylor RL, Sergouniotis PI, 
Horn B, Lamb JA, Michaelides M, Webster AR, Newman WG, Panda B, Ramsden SC, 
Black GC. Validation of copy number variation analysis for next-generation sequencing 
diagnostics. Eur J Hum Genet 2017;25:719–24.
 15 Bujakowska KM, Fernandez-Godino R, Place E, Consugar M, Navarro-Gomez D, White 
J, Bedoukian EC, Zhu X, Xie HM, Gai X, Leroy BP, Pierce EA. Copy-number variation is 
an important contributor to the genetic causality of inherited retinal degenerations. 
Genet Med 2017;19.
 16 Van Cauwenbergh C, Van Schil K, Cannoodt R, Bauwens M, Van Laethem T, De 
Jaegere S, Steyaert W, Sante T, Menten B, Leroy BP, Coppieters F, De Baere E. arrEYE: 
a customized platform for high-resolution copy number analysis of coding and 
noncoding regions of known and candidate retinal dystrophy genes and retinal 
noncoding RNAs. Genet Med 2017;19.
 17 Khateb S, Hanany M, Khalaileh A, Beryozkin A, Meyer S, Abu-Diab A, Abu Turky F, 
Mizrahi-Meissonnier L, Lieberman S, Ben-Yosef T, Banin E, Sharon D. Identification of 
genomic deletions causing inherited retinal degenerations by coverage analysis of 
whole exome sequencing data. J Med Genet 2016;53:600–7.
 18 Carss KJ, Arno G, Erwood M, Stephens J, Sanchis-Juan A, Hull S, Megy K, Grozeva D, 
Dewhurst E, Malka S, Plagnol V, Penkett C, Stirrups K, Rizzo R, Wright G, Josifova D, 
Bitner-Glindzicz M, Scott RH, Clement E, Allen L, Armstrong R, Brady AF, Carmichael 
J, Chitre M, Henderson RH, Hurst J, MacLaren RE, Murphy E, Paterson J, Rosser E, 
Thompson DA, Wakeling E, Ouwehand WH, Michaelides M, Moore AT, Webster 
AR, Raymond FL; NIHR-BioResource Rare Diseases Consortium. Comprehensive 
Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular 
Pathology of Inherited Retinal Disease. Am J Hum Genet 2017;100:75–90.
 19 Eisenberger T, Neuhaus C, Khan AO, Decker C, Preising MN, Friedburg C, Bieg A, 
Gliem M, Charbel Issa P, Holz FG, Baig SM, Hellenbroich Y, Galvez A, Platzer K, 
Wollnik B, Laddach N, Ghaffari SR, Rafati M, Botzenhart E, Tinschert S, Börger D, 
Bohring A, Schreml J, Körtge-Jung S, Schell-Apacik C, Bakur K, Al-Aama JY, Neuhann 
T, Herkenrath P, Nürnberg G, Nürnberg P, Davis JS, Gal A, Bergmann C, Lorenz B, 
Bolz HJ. Increasing the yield in targeted next-generation sequencing by implicating 
CNV analysis, non-coding exons and the overall variant load: the example of retinal 
dystrophies. PLoS One 2013;8:18:e78496.
 20 Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics 2009;25:1754–60.
 21 Plagnol V, Curtis J, Epstein M, Mok KY, Stebbings E, Grigoriadou S, Wood NW, 
Hambleton S, Burns SO, Thrasher AJ, Kumararatne D, Doffinger R, Nejentsev S. A 
robust model for read count data in exome sequencing experiments and implications 
for copy number variant calling. Bioinformatics 2012;28:2747–54.
 22 Vijayarangakannan P. CoNVex: Copy Number Variation form Exomes. ftp:// ftp. sanger. 
ac. uk/ pub/ users/ pv1/ CoNVex/ Docs/ CoNVex. pdf2013.
 23 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, 
Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance 
Committee. Standards and guidelines for the interpretation of sequence variants: a 
joint consensus recommendation of the American College of Medical Genetics and 
Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–23.
 24 Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, Cox AJ, 
Kruglyak S, Saunders CT. Manta: rapid detection of structural variants and indels for 
germline and cancer sequencing applications. Bioinformatics 2016;32:1220–2.
 25 Roller E, Ivakhno S, Lee S, Royce T, Tanner S. Canvas: versatile and scalable detection 
of copy number variants. Bioinformatics 2016;32:2375–7.
 26 Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG, Carnevali P, 
Nazarenko I, Nilsen GB, Yeung G, Dahl F, Fernandez A, Staker B, Pant KP, Baccash J, 
Borcherding AP, Brownley A, Cedeno R, Chen L, Chernikoff D, Cheung A, Chirita R, 
Curson B, Ebert JC, Hacker CR, Hartlage R, Hauser B, Huang S, Jiang Y, Karpinchyk V, 
Koenig M, Kong C, Landers T, Le C, Liu J, McBride CE, Morenzoni M, Morey RE, Mutch 
K, Perazich H, Perry K, Peters BA, Peterson J, Pethiyagoda CL, Pothuraju K, Richter C, 
Rosenbaum AM, Roy S, Shafto J, Sharanhovich U, Shannon KW, Sheppy CG, Sun M, 
Thakuria JV, Tran A, Vu D, Zaranek AW, Wu X, Drmanac S, Oliphant AR, Banyai WC, 
Martin B, Ballinger DG, Church GM, Reid CA. Human genome sequencing using 
unchained base reads on self-assembling DNA nanoarrays.  
Science 2010;327:78–81.
 27 Carnevali P, Baccash J, Halpern AL, Nazarenko I, Nilsen GB, Pant KP, Ebert JC, 
Brownley A, Morenzoni M, Karpinchyk V, Martin B, Ballinger DG, Drmanac R. 
Computational techniques for human genome resequencing using mated gapped 
reads. J Comput Biol 2012;19:279–92.
 28 Pirooznia M, Goes FS, Zandi PP. Whole-genome CNV analysis: advances in 
computational approaches. Front Genet 2015;6:138.
 29 Weisschuh N, Mayer AK, Strom TM, Kohl S, Glöckle N, Schubach M, Andreasson 
S, Bernd A, Birch DG, Hamel CP, Heckenlively JR, Jacobson SG, Kamme C, Kellner 
U, Kunstmann E, Maffei P, Reiff CM, Rohrschneider K, Rosenberg T, Rudolph G, 
Vámos R, Varsányi B, Weleber RG, Wissinger B. Mutation detection in patients 
with retinal dystrophies using targeted next gheneration sequencing. PLoS One 
2016;11:e0145951.
 30 Perez-Carro R, Corton M, Sánchez-Navarro I, Zurita O, Sanchez-Bolivar N, Sánchez-
Alcudia R, Lelieveld SH, Aller E, Lopez-Martinez MA, López-Molina MI, Fernandez-San 
Jose P, Blanco-Kelly F, Riveiro-Alvarez R, Gilissen C, Millan JM, Avila-Fernandez A, 
Ayuso C. Panel-based NGS reveals novel pathogenic mutations in autosomal recessive 
retinitis pigmentosa. Sci Rep 2016;6:19531.
 31 Nishiguchi KM, Tearle RG, Liu YP, Oh EC, Miyake N, Benaglio P, Harper S, Koskiniemi-
Kuendig H, Venturini G, Sharon D, Koenekoop RK, Nakamura M, Kondo M, Ueno S, 
Yasuma TR, Beckmann JS, Ikegawa S, Matsumoto N, Terasaki H, Berson EL, Katsanis 
N, Rivolta C. Whole genome sequencing in patients with retinitis pigmentosa reveals 
pathogenic DNA structural changes and NEK2 as a new disease gene. Proc Natl Acad 
Sci U S A 2013;110:16139–44.
 32 Tan R, Wang Y, Kleinstein SE, Liu Y, Zhu X, Guo H, Jiang Q, Allen AS, Zhu M. An 
evaluation of copy number variation detection tools from whole-exome sequencing 
data. Hum Mutat 2014;35:899–907.
 33 Van Schil K, Naessens S, Van de Sompele S, Carron M, Aslanidis A, Van Cauwenbergh 
C, Mayer AK, Van Heetvelde M, Bauwens M, Verdin H, Coppieters F, Greenberg ME, 
Yang MG, Karlstetter M, Langmann T, De Preter K, Kohl S, Cherry TJ, Leroy BP, De 
Baere E. Mapping the genomic landscape of inherited retinal disease genes prioritizes 
genes prone to coding and noncoding copy-number variations. Genet Med 2017.
 34 Carvalho CM, Lupski JR. Mechanisms underlying structural variant formation in 
genomic disorders. Nat Rev Genet 2016;17:224–38.
 35 Yuan B, Liu P, Gupta A, Beck CR, Tejomurtula A, Campbell IM, Gambin T, Simmons 
AD, Withers MA, Harris RA, Rogers J, Schwartz DC, Lupski JR. Comparative Genomic 
Analyses of the Human NPHP1 Locus Reveal Complex Genomic Architecture and Its 
Regional Evolution in Primates. PLoS Genet 2015;11:e1005686.
 36 Fowler A, Mahamdallie S, Ruark E, Seal S, Ramsay E, Clarke M, Uddin I, Wylie H, 
Strydom A, Lunter G, Rahman N. Accurate clinical detection of exon copy number 
variants in a targeted NGS panel using DECoN. Wellcome Open Res;1:20
 37 Martin-Merida I, Sanchez-Alcudia R, Fernandez-San Jose P, Blanco-Kelly F, Perez-Carro 
R, Rodriguez-Jacy da Silva L, Almoguera B, Garcia-Sandoval B, Lopez-Molina MI, Avila-
Fernandez A, Carballo M, Corton M, Ayuso C. Analysis of the PRPF31 Gene in Spanish 
Autosomal Dominant Retinitis Pigmentosa Patients: A Novel Genomic Rearrangement. 
Invest Ophthalmol Vis Sci 2017;58:1045–53.
 38 Rose AM, Bhattacharya SS. Variant haploinsufficiency and phenotypic non-penetrance 
in PRPF31-associated retinitis pigmentosa. Clin Genet 2016;90:118–26.
 39 Zaneveld J, Siddiqui S, Li H, Wang X, Wang H, Wang K, Li H, Ren H, Lopez I, 
Dorfman A, Khan A, Wang F, Salvo J, Gelowani V, Li Y, Sui R, Koenekoop R, Chen R. 
Comprehensive analysis of patients with Stargardt macular dystrophy reveals new 
genotype-phenotype correlations and unexpected diagnostic revisions. Genet Med 
2015;17:262–70.
 40 Zernant J, Xie YA, Ayuso C, Riveiro-Alvarez R, Lopez-Martinez MA, Simonelli F, Testa F, 
Gorin MB, Strom SP, Bertelsen M, Rosenberg T, Boone PM, Yuan B, Ayyagari R, Nagy 
PL, Tsang SH, Gouras P, Collison FT, Lupski JR, Fishman GA, Allikmets R. Analysis of 
the ABCA4 genomic locus in Stargardt disease. Hum Mol Genet 2014;23:6797–806.
group.bmj.com on January 22, 2018 - Published by http://jmg.bmj.com/Downloaded from 
diseases
sequencing testing for inherited retinal
surveillance into gene panel next-generation 
Assessment of the incorporation of CNV
Black
Michaelides, Simon C Ramsden, Andrew R Webster and Graeme C M 
Sergouniotis, Rachel L Taylor, Keren J Carss, Lucy F L Raymond, Michel
Stephanie Barton, Catriona Tate, Sanjeev Bhaskar, Panagiotis I 
Jamie M Ellingford, Bradley Horn, Christopher Campbell, Gavin Arno,
 published online October 26, 2017J Med Genet
 http://jmg.bmj.com/content/early/2018/01/05/jmedgenet-2017-104791
Updated information and services can be found at: 
These include:
References
 #ref-list-1
http://jmg.bmj.com/content/early/2018/01/05/jmedgenet-2017-104791
This article cites 33 articles, 4 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (200)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 22, 2018 - Published by http://jmg.bmj.com/Downloaded from 
